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Background: Previous studies have indicated that acupuncture can alleviate the symptoms of Tourette syndrome
(TS), but the evidence is insufficient. So far, there have been no reports on plum-blossom needle therapy for TS.
Here we present a protocol for a randomized controlled trial using plum-blossom needle therapy to treat TS.
Methods/design: Sixty patients will be randomly allocated into either the plum-blossom needle therapy group or
the habit reversal training (HRT) group. All patients in each group will be given 12 weeks of treatment, with follow-up
at the 24th week. The primary outcome measure will be the mean change from baseline in the total tic score on the
Yale Global Tic Severity Scale (YGTSS) at the 12th week. Secondary outcome measures will include the scores on the TS
Clinical Global Impression Scale (CGI) and the mean changes from baseline in the YGTSS score and the Children and
Adolescents’ Quality of Life Scale (CAQOL) at other time points. Safety will also be evaluated.
Discussion: This trial will evaluate the effectiveness and safety of plum-blossom needle therapy for TS compared with
HRT. A limitation of this trial is that patients and acupuncturists cannot be blinded.
Trial registration: ClinicalTrials.gov Identifier: NCT02403258 (Date of registration: March 31, 2015).
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Tourette syndrome (TS) is a childhood-onset chronic
neuropsychiatric disorder characterized by multiple
motor tics and one or more vocal tics, with a duration
of at least 1 year [1]. Population-based studies indicate
that TS affects approximately 0.3–1 % of children in
Western countries [2–6] and 0.43–0.56 % of children in
China [7, 8]. TS is two to four times more common in
boys than girls [5]. The majority of TS cases have co-
morbid conditions such as attention-deficit hyperactivity
disorder, obsessive-compulsive disorder, mood disorders,
learning disorders, self-injurious behavior, and other
behavior disorders. TS and its complications seriously
influence the quality of patients’ lives [9, 10].* Correspondence: liuzhishun@aliyun.com
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creativecommons.org/publicdomain/zero/1.0/The guidelines developed by the European Society
for the Study of Tourette syndrome (ESSTS) in 2011 rec-
ommended that TS could be treated by behavioral therapy
(habit reversal training or exposure with response preven-
tion) and medications including alpha-adrenergic agents,
typical antipsychotics, atypical antipsychotics, and ben-
zamides [11, 12]. Although there is strong evidence in
favor of pharmacological intervention, it is also known
that medications can rarely eradicate tics completely
and are always associated with unwanted side effects.
The most commonly observed adverse events of typical
antipsychotics are extrapyramidal reactions, neuroleptic
malignant syndrome, drowsiness, restlessness, and sex-
ual dysfunction; sulpiride may lead to sustained sed-
ation or drowsiness [13–15].
Acupuncture is a conventional Traditional Chinese
Medicine method that dates back thousands of years,
and it has specifically been used to treat TS for manydistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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controlled trials published in 2010 revealed that acu-
puncture was probably more effective for TS than
medications [16]. However, the included studies were
all published in Chinese, with the limitations of small
sample sizes and poor design quality; the systematic
review could not provide sufficient evidence to sup-
port the effectiveness of acupuncture in treating TS.
At present, many parents in China seek treatment from
Traditional Chinese Medicine practitioners for their chil-
dren with TS. However, maintaining a fixed position dur-
ing conventional acupuncture is difficult for children, and
the pain associated with conventional acupuncture leads
to poor compliance. Plum-blossom needle therapy is a
method of shallow insertion of multiple needles into the
skin. The treatment instrument is made of five or seven
stainless-steel needles arranged in a plum-blossom-shaped
pattern, hence the name ‘plum-blossom needle.’ Plum-
blossom needle therapy treats diseases by tapping specific
skin areas or acupoints corresponding to the treatment of
different illnesses based on the meridian theory. Our pilot
study in which we used self-made blunt-pointed plum-
blossom needles showed that plum-blossom needle ther-
apy can relieve the symptoms of TS. The treatment was
well accepted by children with TS because of its mild pain
as the needles did not pierce the skin.
This protocol is designed for phase II of our trial. The
objective of this trial is to evaluate the effectiveness and
safety of plum-blossom needle therapy for treating TS.Methods/design
Study design
This protocol is for a prospective randomized con-
trolled trial. Randomization will be performed by the
Good Clinical Practice (GCP) office of Guang’anmen
Hospital of the China Academy of Chinese Medical Sci-
ences. Statistics Analysis System software version 9.1.3
(SAS Institute, Cary, NC, USA) will be used to generate
the random allocation sequence with a block of four.
Opaque sealed envelopes will be used. Patients' se-
quence numbers are printed on the envelope surface.
The random allocation sequence numbers and group
names are inside the envelope. The randomization pro-
gram will be saved by an appointed staff member in the
GCP office who will not take part in this trial.
The trial will be conducted in Guang’anmen Hospital
over 3 years from 1 January 2015 to 30 May 2018. We
plan to recruit participants via advertisements in newspa-
pers, television, websites, and posters. Eligible participants
diagnosed with TS by a psychiatrist will be randomly
assigned into the plum-blossom needle therapy group or
the HRT group at a 1:1 ratio. A flowchart of the trial pro-
cedure is presented in Fig. 1.The duration of the study will be 25 weeks, including a
baseline period of 1 week (week 0–1), a treatment period
of 12 weeks (week 1–12), and a follow-up period of
12 weeks (week 13–24). The timeline of the trial is pre-
sented in Fig. 2.
Ethical approval
All procedures will be explained to patients and their
guardians; the informed consent form will be reviewed
and signed by each participant and their guardian be-
fore randomization. The trial protocol is in accordance
with the principles of the Declaration of Helsinki (ver-
sion Edinburgh 2000) and has been approved by the
Ethics Committee of Guang’anmen Hospital, China
Academy of Chinese Medical Sciences (ethics approval
no. 2014EC104).
Participants
A target sample of s60 participants with TS will be
recruited in the trial.
Inclusion criteria
1. Participants must meet the diagnostic criteria of
the Diagnostic and Statistical Manual of Mental
Disorders of the American Psychiatric Association
(DSM-IV-TR) for TS: Both multiple motor and
one or more vocal tics have been present at some
time during the illness, although not necessarily
concurrently. The tics occur many times (usually
in bouts) nearly every day or intermittently
throughout a period of more than 1 year; during
this period there was never a tic-free period of more
than 3 consecutive months. Onset was before the age
of 18 years. The disturbance is not due to the direct
physiological effects of a substance (e.g., stimulants)
or a general medical condition (e.g., Huntington’s
chorea or postviral encephalitis) [1].
2. Age 7 to 18 years.
3. Participants must agree to participate in the trial,
and both guardians and subjects must sign written
informed consent.
Exclusion criteria
1. TS patients with concurrent severe problems
involving the heart, liver, or kidney, or with
hyperthyroidism.
2. After evaluation by psychiatrists based on the Kiddie-
Sads-Present and Lifetime Version, those who have
comorbid conditions such as mental retardation,
pervasive developmental disorder, schizophrenia,
manic episode, bipolar disorder, anxiety and depression,
or a specific learning disorder will be excluded.
Fig. 1 Flowchart of the proposed trial procedure
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4. Subjects who are using pharmacological or non-
pharmacological treatment for TS have to be free
from that for at least 2 weeks prior to baseline
assessment.5. Patients with a history of psychotropic substance or
alcohol use during the 3 months preceding
screening.
6. Patients with a history of non-responsiveness to
HRT and those participating in another clinical trial.
Fig. 2 Proposed timeline of the trial
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Lifestyle education will be taught to all parents/guard-
ians of patients, including the stability and unity of the
family, not being strict with their children, and reducing
patients’ psychological burden. Patients will also be re-
quired to abstain from exciting novels and films. All par-
ticipants must not receive any other therapy for TS
during the trial.
Plum-blossom needle therapy group
The acupoints were selected based on our pilot study
and consensus with experienced acupuncture experts.
The points will be DU20 (Baihui), DU16 (Fengfu),
GB20 (Fengchi), EX-HN5 (Taiyang), BL15 (Xinshu),
BL18 (Ganshu), and BL23 (Shenshu). Self-made head-
detachable sterile plum-blossom needles will be used in
this trial (see Fig. 3). After the skin has been wiped with
75 % alcohol, plum-blossom needles will be tapped per-
pendicularly on the skin at the selected acupoints with
wrist force and then lifted immediately (see Fig. 4).
Each point will be tapped repeatedly for 30 s and totally
6 min for each session. Acupuncturists should tap the
points gently to make patients feel only a little pain and
stop when the skin gets flushed but is not bleeding.
The treatment will be two sessions per week forFig. 3 Composition of the plum-blossom needle with a detachable head. Eac
high pressure after each use12 weeks (24 sessions in all). Treatments will be done
by acupuncturists with over 2 years of working experi-
ence and academic credentials above an undergraduate
degree; they will be trained specifically for this protocol
prior to the trial.
HRT group
HRT will consist of the following: (1) self-monitoring,
(2) competing responses, (3) relaxation training, and (4)
contingency management. Self-monitoring will be done
to increase patients’ awareness of premonitory sensa-
tions or urges and to obtain detailed descriptions of var-
ied tic symptoms. Patients will be provided with charts
in which they can record the occurrence of tics, preced-
ing sensations/urges, and the muscles and movements
involved in a tic. Competing response training will
involve each patient being trained to perform more
appropriate physical responses when they feel the urge
to perform tics, thereby preventing tic occurrence. For
example, patients with arm jerking tics will be trained
to contract the tic-opposing muscles when they are
aware of the early sensations or urges preceding tics.
For vocal tics, competing responses such as closing the
mouth and breathing slowly through the nose will be
used to avoid occurrence of tics. For complex tics,h needle head will be used for a specific patient and will be sterilized at
Fig. 4 Manipulation of the plum-blossom needle
Yu et al. Trials  (2015) 16:320 Page 5 of 7competing responses for individual components will be
developed first and then chained. Patients will also be
taught the relaxation techniques of thoracic breathing
and diaphragmatic breathing. Treatment will typically
be started with the patients’ most bothersome tics, unless
the patient and clinician determine that competing
responses for a less bothersome tic would be easier to im-
plement before moving on to a more bothersome/severe/
complex tic [17, 18]. The HRT training will be given
weekly for 12 weeks (12 sessions in total) by a special
rehabilitation therapist. The first two sessions will be
1.5 h, and the remaining sessions will be 1 h for each
treatment.
Outcome measures
The primary outcome measure will be the mean change
from baseline in the total tic score on the Yale Global
Tic Severity Scale (YGTSS) at the 12th week.
Secondary outcome measures will include the mean
change from baseline in the YGTSS score at the 4th, 8th,
and 24th week, the mean score on the TS Clinical Global
Impression Scale (CGI) at the 4th, 8th, 12th, and 24th
week, and the mean score change compared with baseline
on the Children and Adolescents’ Quality of Life Scale
(CAQOL) at the 12th and 24th week.
Adverse events including fainting, stabbing pain dur-
ing acupuncture, fatigue, insomnia, appetite change,
worsening of symptoms, local infections, and other side
effects related to acupuncture will be recorded in detail
by patients, their parent/guardian, acupuncturists, and
interviewers.
The outcome assessments will be done by research
assistants who are blinded to the clinical management.Quality control and data collection
All staff involved in the trial will receive training before
the trial commences. The training program will include
case screening, intervention method, evaluation of out-
come measures, completion of case report forms (CRFs),
and data management.
Two data managers with medical backgrounds will
check the data recorded in the CRFs. After a data re-
view, two research assistants will independently input
the data using EpiData software (EpiData Association,
Odense, Denmark). The data will then be submitted to a
statistician independent from the research team for final
analysis.
Sample size and statistical analysis
The reduction in YGTSS score in the pilot trial after
12 weeks of treatment in the plum-blossom needle ther-
apy group and HRT group was 13.12 ± 5.40 (mean ±
standard deviation) and 9.50 ± 3.20 (mean ± standard
deviation), respectively. Using a one-sided superiority
test (α = 0.025), 30 patients will be required in each
group to give a power of 80 %, allowing for a 20 % drop-
out (1:1 ratio).
The outcome parameters of randomized patients will
be analyzed on an intention-to-treat basis. Missing data
will be replaced by the last entry. All outcome measures
will be analyzed by two-sided tests. All significance levels
will be established at 0.05. Continuous data will be rep-
resented by the mean, standard deviation, median, mini-
mum value, and maximum value; categorical data will be
represented by percentages. A t-test or nonparametric
test will be used for continuous data. A chi-square test
or Fisher’s exact test will be used for categorical data.
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exact test will be done to compare the incidence of side
effects between the two groups. Analyses will be per-
formed using SPSS version 13.0 software (SPSS Inc.,
Chicago, IL, USA).
Discussion
Traditional plum-blossom needles pierce the skin when
treating disease. However, to improve patient compli-
ance in this proposed trial, we will use self-made blunt-
pointed plum-blossom needles that will not pierce the
skin and hence will alleviate the pain during treatment.
The primary aim of this study is to evaluate the effect-
iveness of plum-blossom needle therapy for TS. As the
blunt-pointed plum-blossom needles will not pierce the
skin, we cannot feasibly conduct sham plum-blossom
needle therapy or placebo as a control group. HRT, rec-
ommended as an effective and safe TS treatment by the
ESSTS, is the most extensively researched behavioral
treatment for tics. Hence, comparing plum-blossom nee-
dle therapy with HRT will reflect the effectiveness and
clinical value of plum-blossom needle therapy for TS.
Most studies of HRT for TS have 10–14-week-long
treatment, with follow-up data at 1 month to 1 year,
mostly 3 months post-treatment. Thus, it is appropriate
to conduct the follow-up visit at the 24th week after the
last-time treatment [12, 19–21]. We will therefore
measure the primary outcome at the 12th week, but we
will also observe the changes in outcome measurements
at the 4th, 8th, and 24th week to observe the time of
onset and maintenance of the effect produced by plum-
blossom needle therapy. In this trial, patients and acu-
puncturists will not be blinded, which means bias cannot
be avoided. However, we can partially avoid biases
caused by expectations and subjective assessment via
rigid randomization, concealment of the allocation, and
blinding of outcome assessors and statisticians. Other-
wise, the outcome of this trial could not exclude the
possible placebo effect of plum-blossom needle therapy,
so we would not know its true efficacy.
Trial status
The first participant was included on 3 January 2015. To
date, two participants have been recruited.
Consent
Written informed consent will be obtained from the
patient(s) for publication of this manuscript and accom-
panying images. A copy of the written consent is available
for review from the Editor-in-Chief of this journal.
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